RxDoctor Payments Data

Ravinder Kurl, MD

Internal Medicine · Stockbridge, GANPI 1386737666

Payments from drug & device makers

$2,227in general payments, 2019–2025

Across 71 payments — averaging $31.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Bayer$206
  • Astellas Pharma US Inc$198
  • Novo Nordisk$173
  • Radius Health, Inc.$111
  • Abbott$94
  • plus $418 from 9 others

What the payments were for

  • Food & beverage$2,03591%
  • Education$1929%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,227 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$114,788
Medicare patients
158
Services billed
1,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$90,290
JardianceEmpagliflozin51$75,987
FarxigaDapagliflozin Propanediol32$47,893
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$45,929
TrulicityDulaglutide16$35,668
EliquisApixaban23$27,693
JanumetSitagliptin Phos/Metformin Hcl13$21,112
EntrestoSacubitril/Valsartan13$15,611
MounjaroTirzepatide12$12,194
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$10,760
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,112
Breo ElliptaFluticasone/Vilanterol11$4,603
Diclofenac Sodium102$4,550
Albuterol Sulfate HfaAlbuterol Sulfate127$4,262
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$173$90,29048 claims
Boehringer IngelheimJardiance$17$75,98751 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,027$58,65249 claims
GSKTrelegy Ellipta, Breo Ellipta$79$50,53268 claims
Lilly USA, LLCTrulicity, Mounjaro$53$47,86228 claims
PfizerEliquis$19$27,69323 claims
NovartisEntresto$42$15,61113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →